Sai Life Sciences Expands CDMO Operations Beyond China-Plus-One Strategy

Sai Life Sciences is capitalising on a broader industry shift toward supply chain diversification, expanding its contract research, development and manufacturing (CRDMO) operations to serve multinational pharmaceutical firms seeking alternatives to concentrated manufacturing bases in China. The Hyderabad-headquartered company is investing in capacity expansion while broadening its service portfolio to include peptides and formulation development, positioning itself as a preferred outsourcing partner for global drug makers reassessing their sourcing strategies.

The expansion reflects growing momentum in India's pharmaceutical manufacturing sector, as companies worldwide implement a "China-Plus-One" strategy and increasingly a "China-Plus-Many" approach to mitigate geopolitical and supply chain risks. Sai Life Sciences' move into higher-value segments such as peptides and formulations allows it to capture greater market opportunity as pharmaceutical companies consolidate their outsourcing relationships with fewer, more capable partners.

The company is expecting stronger financial performance in the second half of FY27, driven by revenue growth from its expanded operations and enhanced service offerings. This trajectory underscores robust demand from multinational pharmaceutical firms seeking to establish or strengthen relationships with Indian CDMOs capable of handling complex manufacturing requirements.

The development represents a significant opportunity for India's pharmaceutical sector, which has traditionally dominated the finished dosages and active pharmaceutical ingredients markets. The growing acceptance of Indian CDMOs by global pharmaceutical companies for complex manufacturing further cements India's position in the global drug manufacturing value chain.